

### Disclaimer




This presentation brings statements about future events that are subject to risks and uncertainties. Such statements are based on our Management's beliefs and assumptions and on information that the Company currently has access to. Statements about future events include information regarding our intentions, beliefs or current expectations, as well as those of the members of the Management Board and Company Directors.

Disclaimers according to the statements and the information about the future also include information about possible or presumed operating results, as well as statements preceded by, followed by or that include the words "believes", "may", "will", "continue", "expects", "anticipates", "intends", "plans", "estimates" or similar expressions.

The statements and information are not guarantees of future performance. They involve risks, uncertainties and assumptions because they are related to future events and, therefore, depending on circumstances that may or may not occur. Future results and value creation for our shareholders may differ materially from those expressed or implied by the statements made about the future. Many of the factors that will determine these results and values are beyond our ability to control or predict.



# **Total Net Revenue**



# Net Revenue by Segment



# Net Revenue by Segment **Companion Animals** (R\$ million) 8.4% 46.5 42.9 40.2% 15.7 11.2 3Q16 3Q17 9M16 9M17


# Net Revenue by Segment




# Gross Profit and Gross Margin



# Gross Profit and Gross Margin by Segment



# Gross Profit and Gross Margin by Segment



# Gross Profit and Gross Margin by Segment



SG&A
(R\$ million)

-12.6%






—Percentage on net revenue

# Adjusted EBITDA

(R\$ million)


Financial Performance



# **Net Financial Expense**

(R\$ million)





# **Income Tax**

(R\$ million)

# Financial Performance



—Tax rate

# Net Profit

(R\$ million)

# Financial Performance




# **Net Debt and Equity**

(R\$ million)

### Indebtedness

**EBITDA** 

30th 1




Note 1: Average cost calculated on the debt considering linked derivatives.

# Debt Aging<sup>1</sup>

(R\$ million)


# Indebtedness



- Cash position of R\$ 112 million
- Advanced negotiations with FINEP for a new credit facility of R\$ 70 million

# Generation of Cash


(R\$ million)



# R&D



(R\$ million)



# Launches in 9M17

Production Animals



# Superhion 5L

Superhion is a pour-on ectoparasiticide for cattle, composed by the association between Fipronil and Fluazuron, recommended for the strategic control of ticks and horn flies and for the treatment against botflies and myiasis.

# Launches in 9M17

Companion Animals



# Regepil

For treatment of general, chronic and localized wounds in areas of difficult healing;

Surgical wounds helping in reducing the dehiscence index of stitches;

Contribute and accelerate the healing process in animals with physiological impairment.

# **Q&A Session**

